Oral 7HP349 with immunotherapy for advanced solid tumors
Treatments studied
Part of Cancer, Digestive system, Kidney & urinary, Lungs & breathing, Skin, Women’s health & pregnancy clinical trials.
This trial tests an experimental oral drug (7HP349) combined with two immunotherapy drugs (ipilimumab and nivolumab) for people with advanced solid tumors. It aims to see if the combination is safe and effective in shrinking tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have one of these cancers: melanoma, pleural mesothelioma, kidney cancer, MSI-high colorectal cancer, liver cancer, non-small cell lung cancer (without certain gene changes), or another type where the combination of ipilimumab and nivolumab is FDA-approved.
- You are able to do daily activities without much help (ECOG score 0 or 1).
- Your blood counts (ANC, hemoglobin, platelets) are at certain levels, and your kidney and liver function tests are within acceptable ranges.
- You have not had active brain metastases in the last 4 weeks, and you are not on steroids for brain metastases.
- You have not had severe side effects from prior immunotherapy, and you are not taking strong medications that affect a liver enzyme called CYP3A4.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests a combination of three immune “checkpoint” medicines in people with advanced solid cancers. It aims to see how well they work and what side effects occur, including when given through a specific liver-focused treatment in eligible patients.
This trial tests an experimental drug called IPN01203 for people with advanced solid tumors that have grown after prior immunotherapy. The goal is to see if the drug is safe and can shrink tumors.
This trial tests a new oral drug (HC-7366) combined with two immunotherapy drugs (nivolumab and ipilimumab) for people with advanced clear cell kidney cancer. The goal is to see if adding this new drug can help shrink tumors or slow the cancer's growth.
This early-phase trial studies OMTX705, given by itself or with an anti–PD-1 immune therapy, in people with advanced solid cancers that can’t be cured or that stopped responding to standard treatments. It aims to check safety and see whether the treatment can shrink tumors or control disease.
This early study tests a new medicine (BPI-460372) in adults with advanced solid cancers that have come back or can’t be treated with standard options. It may help by targeting specific cancer changes in certain tumors, and doctors will also learn the safest dose.
This trial tests a new medication for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug can shrink tumors or slow their growth.
Hear when a new Advanced Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.